scholarly journals SP8.1.4 Design features of the EPR-integrated Southampton Breast Cancer Data System (SBCDS), with timeline structured whole-of-life records on 20,000 sequential cases since the 1970s

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Fatima Rahman ◽  
Alan Hales ◽  
David Cable ◽  
David Rew
Keyword(s):  
Breast Cancer ◽  
Primary Diagnosis ◽  
Data System ◽  
Patient Record ◽  
Data Visualisation ◽  
Breast Cancer Data ◽  
Mining System ◽  
Cancer Data ◽  
Breast Neoplasia ◽  
Wide Range

Abstract Introduction The digitisation of the electronic patient record (EPR) provides transformative opportunities for data visualisation. The synchronised timeline and iconographic interface permits the whole-of-life display, navigation and interpretation of all documents and reports of each and every EPR on a single screen, thus substantially facilitating clinical research. Methods Since 2010, we have conceived, programmed and iterated a radical interface, UHS Lifelines, within our Trust EPR using agile methodology. It is live for >2.5M record sets, and enriched with cellular pathology records back to 1990. We have integrated this interface into a unique, HTML-enabled, dynamic and continually updated database for the recording of treatments and pathologies of all cases of breast neoplasia from our current and historic record sets. Results As of January 2021, our data system contains ∼20,000 sequential whole of life records of patients with breast neoplasia, including ∼15,000 locally diagnosed and ∼ 5,000 externally referred cases. The unique Cancer Lifetrack timelines displays the disease course of every case from primary diagnosis, through loco-regional recurrence, to distant metastasis, other morbid cancers and cause of death, where relevant. An integral data mining system permits a wide range of analyses. Conclusions We believe our Breast Cancer Data System to be the first-in-class exemplar of a new and proven approach to clinical data visualisation. It permits near-instantaneous oversight and real time updating of every patient record in the system. We recognise its potential application for the whole-of-life study of all chronic diseases of childhood and adulthood as the model is more widely adopted.

scholarly journals TP8.1.7 The utility of a timeline and episode structured breast cancer data system to study outcomes following neoadjuvant chemotherapy for cases stratified by HER2 status

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Fatima Rahman ◽  
Ellen Copson ◽  
Alan Hales ◽  
David Rew
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Disease Progression ◽  
Data System ◽  
Record Management ◽  
Breast Cancer Data ◽  
Data Set ◽  
Cancer Data ◽  
Wide Range ◽  
Her 2

Abstract Background Breast neoplasia displays complex patterns of whole-of-life disease progression, which are difficult to study using legacy data systems. Our timeline- and episode-structured breast cancer data set of 20,000 records allows direct visualisation of the entire documentary record of every patient. The embedded data mining module permits research into a wide range of patient cohorts by pathology, treatment and outcome. Methods We selected the cohort of patients aged between 15 and 75 with HER-2 –ve and HER-2 +ve breast cancer who were treated with neoadjuvant chemotherapy (NAC), with or without anti-HER2 therapy between 2002 and 2019. We also studied the patterns and time intervals (in months) of disease progression and response to treatment from primary diagnosis, through loco-regional recurrence and distant metastasis to final outcome. Results Of 301 women with confirmed early stage breast cancer were treated with NAC over that time, 186 had HER2- and 115 had HER2+ tumours. The patterns and intervals of disease progression, as displayed on the Master Lifetrack, were mapped and measured for every patient. The proportions of patients with Her2+ve tumours receiving trastuzumab and analogues, and the tumour responses to treatment, were audited. The underlying data set was validated by review of the original records. Conclusions The whole-of-life timeline structured cancer data system introduces a new direction for clinical data visualisation, record management and user utility in surgical practice. This study validates the model as a tool for the better understanding of treatment effects and longitudinal behaviours in any selected range of cancer phenotypes.

Bayesian Frailty Model for Time to Event Breast Cancer Data

2011 ◽  
Vol 4 (2) ◽  
pp. 8-12
Author(s):  
Leo Alexander T Leo Alexander T ◽  
◽  
Pari Dayal L Pari Dayal L ◽  
Valarmathi S Valarmathi S ◽  
Ponnuraja C Ponnuraja C ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Frailty Model ◽  
Breast Cancer Data ◽  
Time To Event ◽  
Cancer Data

AGE FEATURES OF MOLECULAR-BIOLOGICAL SUBTYPES OF BREAST CANCER IN THE REPUBLIC OF UZBEKISTAN

2018 ◽  
Vol 64 (2) ◽  
pp. 196-199
Author(s):  
Gulya Miryusupova ◽  
G. Khakimov ◽  
N. Shayusupov
Keyword(s):  
Breast Cancer ◽  
Cancer Care ◽  
Indigenous Women ◽  
Morbidity And Mortality ◽  
Breast Cancer Data ◽  
Female Population ◽  
Cancer Data ◽  
Age Related ◽  
The Republic ◽  
Age Features

According to the results of breast cancer data in the Republic of Uzbekistan in addition to the increase in morbidity and mortality from breast cancer among women the presence of age specific features among indigenous women in the direction of “rejuvenating” of the disease with all molecular-biological (phenotypic) subtypes of breast cancer were marked. Within the framework of age-related features the prevalence of the least favorable phenotypes of breast cancer was found among indigenous women: Her2/neu hyperexpressive and three times negative subtype of breast cancer. The data obtained made it possible to build a so-called population “portrait” of breast cancer on the territory of the Republic, which in turn would contribute to further improvement of cancer care for the female population of the country.

Genetics testing firm is accused of "hiding vital breast cancer data"

BMJ ◽  
2012 ◽  
Vol 345 (nov01 2) ◽  
pp. e7402-e7402
Author(s):  
N. Hawkes
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Data ◽  
Cancer Data

Screening Breast MRI and Gadolinium Deposition: Cause for Concern?

2021 ◽  
Author(s):  
Colleen H Neal
Keyword(s):  
Breast Cancer ◽  
Renal Function ◽  
Contrast Agents ◽  
Biological Significance ◽  
Breast Mri ◽  
Reliable Data ◽  
Breast Cancer Data ◽  
Cancer Data ◽  
Contrast Enhanced ◽  
Gadolinium Retention

Abstract Gadolinium-based contrast agents (GBCAs) have been used worldwide for over 30 years and have enabled lifesaving diagnoses. Contrast-enhanced breast MRI is frequently used as supplemental screening for women with an elevated lifetime risk of breast cancer. Data have emerged that indicate a fractional amount of administered gadolinium is retained in the bone, skin, solid organs, and brain tissues of patients with normal renal function, although there are currently no reliable data regarding the clinical or biological significance of this retention. Linear GBCAs are associated with a higher risk of gadolinium retention than macrocyclic agents. Over the course of their lives, screened women may receive high cumulative doses of GBCA. Therefore, as breast MRI screening utilization increases, thoughtful use of GBCA is indicated in this patient population.

Sign in / Sign up

Export Citation Format

Share Document